Takeda’s Entyvio, Janssen’s Stelara, and AbbVie’s Humira leave the most on the table when first-line biologic or small molecule agents...
Despite satisfaction among gastroenterologists and allergists who have trialed the drug, high patient out-of-pocket costs and reimbursement hassles could hamper...
Rinvoq and Skyrizi are making waves in ulcerative colitis and Crohn’s disease; is Takeda’s Entyvio in the hot seat? EXTON,...
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and...
AbbVie’s Rinvoq is primed for breakout switching opportunities in the EU5 UC market with its approval by the EMA EXTON,...
The recent loss of the only Phase 3 CeD pipeline candidate highlights the unmet need of suitable treatments for a...
New Spherix Data in Alzheimer’s Disease Reveals High Potential for Emerging Anti-Amyloid Therapies from Genentech, Biogen/Eisai, and Eli Lilly, As...
Spherix’s Eric John reveals preliminary data on two new oral agents and how they are impacting the ulcerative colitis market...
232 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment...
Will the first and only FDA-approved therapy indicated for EoE fill the treatment void expressed by gastroenterologists? EXTON, Pa., June...
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice...
Gastroenterologists report strong awareness, familiarity, and patient initiations for Rinvoq, relative to recent launches EXTON, Pa., June 7, 2022 /PRNewswire...
